Skip to content
Delayed ~15 min

OFIX ORTHOFIX MEDICAL

Health Care · Russell 2000

Next earnings: Mon 9 Nov 2026 · before market open

What 7 analyst firms say about ORTHOFIX MEDICAL: their latest ratings, price targets and how far the stock is from them. How it works

7.87 USD−1.05 (−11.77%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+70.3%to the avg target 13.40 USD+5.53 USD
Buy 4 · Hold 3 · Sell 0

7 rated views · 8 analyst/firm records · 7 firms

Latest report15 Oct 2026avg report date 15 Jul
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8060
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8044

Recent analyst activity · last 90 days

Our tracked history has 3 reports on OFIX from 3 analyst firms in the last 90 days (7 firms in the past year).

Comparing each firm's latest target with its previous one: 1 lowered it and 1 left it unchanged.

No firm's latest available rating differs from its previous one.

Latest observed target change: Barrington Research lowered its target from $17.00 (set 6 Jul 2026) to $14.00 on 15 Oct 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Barrington ResearchMichael J PetuskyBuy15 Oct 202614.00 USD
Canaccord GenuityCaitlin BurrowsBuy10 Aug 202613.00 USD
Canaccord GenuityCaitlin RobertsBuy7 Jul 202613.00 USD
Citizens JMPDavid L TurkalyHold1 Jul 2026—
StifelThomas StephanBuy22 May 202615.00 USD
TD CowenMathew BlackmanHold21 May 202612.00 USD
Weiss RatingsUnnamed analyst—20 Oct 2026—
Data feed RESEARCHResearch TeamHold15 Jun 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 06:56 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.